Erytech Pharma SA
PAR:ERYP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Erytech Pharma SA
PAR:ERYP
|
FR |
|
SKAN Group AG
SIX:SKAN
|
CH |
|
AAC Technologies Holdings Inc
HKEX:2018
|
CN |
Balance Sheet
Balance Sheet Decomposition
Erytech Pharma SA
Erytech Pharma SA
Balance Sheet
Erytech Pharma SA
| Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|
| Assets | ||||
| Cash & Cash Equivalents |
44
|
34
|
39
|
|
| Cash Equivalents |
44
|
34
|
39
|
|
| Short-Term Investments |
0
|
0
|
0
|
|
| Total Receivables |
4
|
5
|
3
|
|
| Accounts Receivables |
0
|
0
|
0
|
|
| Other Receivables |
4
|
5
|
3
|
|
| Inventory |
0
|
0
|
0
|
|
| Other Current Assets |
1
|
1
|
1
|
|
| Total Current Assets |
50
|
40
|
43
|
|
| PP&E Net |
29
|
26
|
3
|
|
| PP&E Gross |
29
|
26
|
3
|
|
| Accumulated Depreciation |
11
|
14
|
11
|
|
| Intangible Assets |
1
|
0
|
0
|
|
| Long-Term Investments |
1
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
0
|
|
| Total Assets |
80
N/A
|
67
-17%
|
46
-31%
|
|
| Liabilities | ||||
| Accounts Payable |
21
|
14
|
5
|
|
| Accrued Liabilities |
4
|
4
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
4
|
2
|
3
|
|
| Other Current Liabilities |
0
|
0
|
0
|
|
| Total Current Liabilities |
29
|
20
|
12
|
|
| Long-Term Debt |
19
|
18
|
10
|
|
| Other Liabilities |
5
|
6
|
0
|
|
| Total Liabilities |
54
N/A
|
44
-18%
|
22
-49%
|
|
| Equity | ||||
| Common Stock |
2
|
3
|
3
|
|
| Retained Earnings |
98
|
79
|
30
|
|
| Additional Paid In Capital |
121
|
98
|
49
|
|
| Other Equity |
2
|
1
|
1
|
|
| Total Equity |
27
N/A
|
23
-14%
|
23
+3%
|
|
| Total Liabilities & Equity |
80
N/A
|
67
-17%
|
46
-31%
|
|
| Shares Outstanding | ||||
| Common Shares Outstanding |
2
|
3
|
3
|
|